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Abstract
Background: Effective HIV treatment with antiretroviral therapy has prolonged sur-
vival and shifted causes of death to non- AIDS illnesses such as cardiovascular dis-
ease. We have shown that inflammation and HIV viral load associate with pro- and 
anticoagulant factor imbalances resulting in increased thrombin generation when 
mathematically modeled. We explore the hypothesis that factor compositional im-
balance, corresponding to increased in silico thrombin generation, predicts mortality 
among HIV+ persons.
Methods: In a nested case- control study of HIV+ individuals on continuous antiretro-
viral therapy in two large trials, we evaluated cases (any non- violent mortality, 
n = 114) and matched controls (n = 318). Thrombin generation in response to a tissue- 
factor initiator for each individual was calculated by a mathematical model incorpo-
rating levels of factors (F)II, V, VII, VIII, IX, X, antithrombin, tissue factor pathway 
inhibitor, and protein C (PC) measured at study entry to the trials. In silico thrombin 
generation metrics included clot time, maximum rate (MaxR), maximum level (MaxL), 
and area under the curve (AUC).
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1  | INTRODUCTION
Aberrant coagulation is a well- described consequence of HIV infec-
tion.1 Deficiencies in key anticoagulants such as protein C (PC)2,3 
and antithrombin (AT)4 have been detected in HIV- infected patients, 
and risk for thromboembolic disease may increase at lower CD4+ 
counts.4 With the development and use of effective antiretroviral 
therapy (ART), morbidity and mortality have been reduced among 
HIV- infected populations. However, rates of non- AIDS defining 
conditions, such as cardiovascular disease, have been increasing.5 
Increases in many chronic diseases would be expected with pro-
longed life expectancy,6 but a key factor contributing to excess rates 
of non- AIDS events among treated HIV+ patients includes persistent 
abnormalities in systemic inflammation and coagulation activity.7–9 
Higher levels of biomarkers such as d- dimer and interleukin- 6 (IL- 
6)8–10 among HIV+ patients have been shown to be positively as-
sociated with anemia,11 cancer,12 cardiovascular disease,10 type 2 
diabetes,13 progression to AIDS,14 and composite non- AIDS related 
clinical events and all- cause mortality.7,8,15 However, a mechanistic 
basis for the connection between HIV- associated alterations in co-
agulation activity and risk for a broad spectrum of non- AIDS defining 
diseases has yet to be elucidated.
Qualitative or quantitative alterations in the proteins and cells re-
sponsible for maintaining the hemostatic balance can result in mor-
bidity and mortality.16,17 At the center of many hemostatic processes 
that regulate bleeding and clotting is the generation of thrombin.18,19 
Thrombin generation is the central event in hemostasis20 and a cul-
prit in thrombosis, whereby the suppression of thrombin production 
and/or function has been proven to be an effective anticoagulant 
therapy.21–23 Thrombin generation assays can be used to define an 
individual’s phenotype through the use of the phases of thrombin 
generation (initiation, propagation, termination) which are governed 
by the underlying kinetic reactions and can provide descriptors of 
the coagulation process (eg, rates, levels, and timing of thrombin 
formation and inhibition).24 Studies in the healthy population have 
shown that thrombin generation dynamics differ largely between 
individuals, but are relatively stable over time in a given individual, 
supporting the concept that they may have utility as a phenotypic 
marker.25–27 The mechanism- based bridge between thrombin gen-
eration assays and individualized risk prediction is plasma compo-
sition–based computational modeling.28,29 Recently, computational 
models that kinetically describe the tissue- factor initiated coagula-
tion process (extrinsic pathway) have been utilized to define an in-
dividual’s thrombin phenotype based upon their individual plasma 
composition of pro- and anticoagulant factors.30
The central idea with this approach is that in any individual, the 
balance of the procoagulant and anticoagulant factor levels together 
act to generate a unique coagulation or thrombin phenotype upon 
a tissue- factor stimulus. We believe that the sum of developmental, 
environmental, genetic, nutritional, and pharmacological influences 
are reflected in the protein levels at any given time that specifically 
alter the synthesis and/or presentation of the proteins and active 
enzymes. We have described changes in thrombin generation and 
related these changes to plasma coagulation factor composition in 
the following groups: genetic bleeding tendencies30–33 and clotting 
tendencies34,35; women undergoing in vitro fertilization36; chronic 
obstructive pulmonary disease37; stroke38; rheumatoid arthritis39; 
and cardiovascular disease.40 In all cases, thrombin generation was 
more pronounced in individuals with procoagulant vs bleeding ten-
dencies.30–32 Individuals with acute conditions appeared to have 
Results: Levels of antithrombin and PC decreased, while FV and FVIII were higher in 
cases vs controls. This resulted in a more procoagulant phenotype with increased 
MaxR, MaxL, and AUC in cases compared to controls (P < 0.05 for all).
Conclusions: Antithrombin, FV, FVIII, and PC were the major contributors to the in-
creased thrombin generation associated with mortality risk. Our results suggest that 
mortality in HIV is associated with an increase in in silico thrombin generation via al-
tered balance of pro- and anticoagulant factors, likely due to an inflammatory re-
sponse signal, and resulting coagulopathy.
K E Y W O R D S
blood coagulation factors, HIV, in silico, inflammation, mathematical model, mortality, 
thrombin generation
Essentials
• Individuals with HIV frequently present with a procoagulant phenotype.
• Thrombin generation was simulated in death cases and matched controls in a HIV cohort.
• Although clot time was unaffected, the cases did produce more thrombin than controls.
• Differences in factors V and VIII, antithrombin, and protein C accounted for this imbalance.
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more pronounced thrombin generation than individuals with chronic 
conditions.38,40 Individuals with inflammatory diseases displayed a 
wide range of thrombin generation.37,39
We previously used this approach to study the consequences of 
HIV viral replication.41 We found short- term increases in factor (F)
VIII and decreases in both AT and PC when HIV replication increased 
after stopping ART; reciprocal changes occurred after initiating ART. 
The protein concentrations for both groups (treated and untreated 
HIV infection) were within the normal ranges for healthy individu-
als, however, these differences resulted in significantly increased 
thrombin generation during untreated HIV infection, which was 
shown to be reversible with ART treatment. Whether this increased 
procoagulant potential translates into a higher risk of adverse clinical 
endpoints is unknown. In this nested case- control study, we report 
associations between mortality risk and computationally generated 
thrombin generation among HIV+ patients treated with ART.
2  | PATIENTS AND METHODS
2.1 | Study population
The study design was a nested case- control study, sampling patients 
from the control arms (continuous use of ART) of two large, inter-
national HIV clinical outcome trials, Strategies for Management of 
Antiretroviral Therapy (SMART)42,43 and Evaluation of Subcutaneous 
Proleukin in a Randomized International Trial (ESPRIT).44 In SMART, 
5472 HIV- positive adults with CD4+ cell count >350 cells/mm3 in 
33 countries were randomized to receive continuous ART with the 
goal of viral suppression (control group) or episodic ART guided by 
the CD4+ count. In ESPRIT, 4111 HIV- positive adults with CD4+ 
cell counts ≥300 cells/mm3 in 25 countries were randomized to re-
ceive continuous ART alone (control group) or continuous ART in 
combination with subcutaneous IL- 2. Therefore, participants in the 
control arms of SMART and ESPRIT received continuous ART along 
with standard of care according to HIV treatment guidelines.
Cases were defined as death from any non- violent cause 
(n = 114) during follow- up (median 3 years), and were matched with 
controls based on age, enrollment date, study, and continent (three 
controls for every one case). Twenty- four controls were omitted due 
to an insufficient blood sample to measure factor levels; the remain-
der (n = 318) were included in our analyses. All participants provided 
written informed consent.
2.2 | Measurement of factor levels and 
other biomarkers
Blood was collected using EDTA (ethylenediaminetetraacetic acid) 
tubes and plasma was processed, frozen at −70°C, and stored at a 
central repository until analysis. Procoagulants FII, FV, FVII, FVIII, 
FIX, and FX were measured using an ELISA (Enzyme Research 
Laboratories, South Bend, IN); analytical inter- assay coefficients 
of variation (CV) range for these measures were 6.4%- 11.1%, 
9.6%- 10.8%, 6.7%- 12.2%, 3.8%- 5.2%, 7.4%- 7.8% and 5.8%- 8.0%, 
respectively. AT was measured on a Stago STA- R analyzer (Stago 
Diagnostics, Parsippany, NJ); with a CV range of 2.6%- 10.2%. PC and 
tissue factor pathway inhibitor (TFPI) were measured using ELISAs 
(Stago Diagnostics and R&D Systems, Minneapolis, MN, respec-
tively). Corresponding CV ranges were 5.5%- 6.2% and 8.8%- 11.3%. 
The assays were standardized with EDTA plasma. All measurements 
used the sample collected at trial entry. Factors are expressed as 
percentages of the mean values in the healthy population.
IL- 6 was measured by ELISA (R&D Systems). d- dimer was mea-
sured using the Liatest D- DI (Stago Diagnostics) for SMART or on 
a VIDAS instrument (BioMerieux Inc., Durham, NC) for ESPRIT. 
High- sensitivity C- reactive protein (hsCRP) was measured by ELISA 
(Siemens Diagnostics, Munich, Germany for SMART and R&D 
Systems for ESPRIT).
2.3 | Computational model of thrombin generation
Mathematical simulations of tissue factor–initiated thrombin gener-
ation were produced as previously described.45 For each individual, 
concentrations of procoagulants FII, FV, FVII(a), FVIII, FIX, and FX 
and anticoagulants TFPI, AT, and PC are electronically “exposed” to 
5 pM tissue factor (TF) in the presence of 1 nmol/L thrombomodulin. 
Simulated reactions were solved for thrombin over a 1200 seconds 
time frame. Individual profiles can be summarized by parameters 
describing the initiation, propagation, and termination phases of 
in silico thrombin generation: maximum level of thrombin genera-
tion (MaxL), maximum rate of thrombin generated (MaxR), time to 
10 nmol/L thrombin (clot time), and total thrombin generated (area 
under the curve [AUC]).46 Results for a particular group of individu-
als are graphically presented as a curve, which represents the mean 
thrombin concentration at each second of the reaction (± standard 
error of the mean). In silico thrombin generation from a hypothetical 
“control” is defined as all factors set at 100% of the mean physiologic 
concentration for each factor.
To determine which factor(s) were responsible for differences 
between cases and controls, we used a previously described proce-
dure39,40 in which each of the individuals in the mortality group had 
one of the factor levels sequentially adjusted to the mean of the con-
trol group and the reaction rerun with a 5 pmol/L TF stimulus and in sil-
ico thrombin outputs recalculated. This process was repeated for each 
factor (and expanded to multiple factors simultaneously). The impact 
of a given factor was evaluated by quantifying the differences between 
various thrombin generation parameters pre- and post- adjustment.
2.4 | Statistical methods
We evaluated the effect of variables used to describe the initiation, 
propagation, and termination phases of thrombin generation, base-
line characteristics, and initial protein concentrations on the risk of 
mortality with conditional logistic regression analyses for matched 
case- control studies. Odds ratios (OR) for mortality per 1 log2 in-
crease in factor levels and modeling parameters are cited. A 1 log2 
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increase corresponds to a two times higher factor level or mode-
ling parameter. To assess whether associations between maximum 
thrombin level and mortality varied by subgroups, an interaction 
term (product of log2 level and subgroup indicator) was included in 
the logistic models. The effect of adjusting for individual factor lev-
els on the maximum level OR for mortality was assessed.
3  | RESULTS
3.1 | Participant characteristics
Table 1 presents the participant demographic and clinical charac-
teristics at trial entry. Distribution of underlying causes of death 
are included in Table 2, with the most frequent causes being non- 
AIDS defining cancer (n = 27; 23.7%), unknown (n = 16; 14.0%), 
cardiovascular disease (CVD) (n = 15; 13.2%), unwitnessed death 
(n = 12; 10.5%), liver disease (n = 10; 8.8%) and AIDS (n = 10; 
8.8%). The median age was 46, and 81% were male. When com-
pared to controls, cases had higher prevalence of viral hepatitis co-
infection, prior CVD, smoking, and use of blood pressure–lowering 
therapy. Baseline use of non- nucleoside reverse transcriptase in-
hibitors (48.2%), protease inhibitors (44.7%), abacavir (24.8%), and 
tenofovir (10.2%) was similar between cases and controls. Cases 
were less likely to be virologically suppressed and had significantly 
higher levels of high- sensitivity C- reactive protein (hsCRP), IL- 6, 
and d- dimer.
Cases Controls P- valuea
Number 114 318
Age (median, IQR) 47 (40- 54) 46 (40- 53) N/A
Female (%) 19.3 19.2 0.98
Black race (%) 20.2 17.3 0.36
White race (%) 73.7 72.3
Other race (%) 6.1 10.4
BMI (median, IQR) 23.4 (21.2- 27.1) 24.5 (22.6- 26.9) 0.18
CD4+ (cells/mm3) (median, 
IQR)
460 (371- 630) 499 (405- 660) 0.15
Nadir CD4+ (cells/mm3) 
(median, IQR)
194 (84- 297) 201 (98- 320) 0.16
HIV RNA (% ≤500 copies/mL) 66.7 76.1 0.036
Hepatitis B or C co- infection 
(%)
33.7 18.6 0.002
BP- lowering treatment (%) 23.7 15.4 0.025
Lipid lowering treatment (%) 19.3 15.7 0.40
Diabetes (%) 8.8 7.2 0.65
Prior CVD (%) 9.6 3.1 0.005
Current smokerb (%) 59.3 37.9 0.009
Total cholesterolb (mg/dL) 
(median, IQR)
190 (165- 238) 202 (176- 234) 0.39
HDL cholesterolb (mg/dL) 
(median, IQR)
40 (31- 53) 41 (33- 50) 0.68
LDL cholesterolb (mg/dL) 
(median, IQR)
111 (84- 134) 111 (88- 133) 0.64
Triglyceridesb (mg/dL) (median, 
IQR)
168 (110- 251) 219 (149- 324) 0.32
Total/HDL ratiob (median, IQR) 4.5 (3.6- 6.4) 5.1 (3.8- 6.5) 0.62
hsCRP (μg/mL) (median, IQR) 3.10 (1.59- 7.61) 1.77 (0.79- 3.84) 0.005
Interleukin- 6 (pg/mL) (median, 
IQR)
3.10 (2.10- 4.48) 1.90 (1.30- 3.00) <0.001
d- dimer (μg/mL) (median, IQR) 0.34 (0.23- 0.54) 0.26 (0.15- 0.39) 0.008
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, high density lipopro-
tein; hsCRP: high- sensitivity C- reactive protein; IQR, interquartile range; LDL, low density 
lipoprotein.
aFrom univariate conditional logistic regression model. 
bAvailable only for SMART participants (n = 54 cases and 153 controls). 
TABLE  1 Participant demographic and 
clinical characteristics
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3.2 | The pro- and anticoagulant balance in 
HIV mortality
Concentrations of plasma factors (expressed as a percentage of 
mean physiologic values in the healthy population) are shown in 
Table 3. In the unadjusted comparisons, the cases had higher pro-
coagulants FVIII (P = 0.003) and FV (P = 0.018), but lower anticoagu-
lants PC (P = 0.002) and AT (P = 0.034). After adjustment for age, sex, 
and race, FVIII (OR 1.80; 95% CI 1.16- 2.80; P = 0.009), FV (OR 1.73; 
95% CI 1.10- 2.71; P = 0.017), and PC (OR 0.45; 95% CI 0.26- 0.77; 
P = 0.003) remained significantly associated with mortality risk.
3.3 | Thrombin generation
The mean thrombin generation (±SEM) for cases and HIV+ controls 
are shown in Figure 1 along with a dashed line representing the 
100% mean physiologic curve. Thrombin generation was increased, 
representing a more procoagulant potential, in both groups of HIV+ 
individuals (cases and controls) over a mean physiologic thrombin 
profile, with mortality cases having the higher thrombin generating 
procoagulant potential when compared to controls. From the indi-
vidual profiles, parameters that objectively characterize the kinetic 
reaction of thrombin generation (MaxR, MaxL, AUC, and clot time) 
were extracted and are presented by group in Table 4. The OR for 
mortality risk per log2 higher level for each thrombin generation pa-
rameter is also presented in Table 3. Although clot time was similar 
between the two groups, the thrombin generation parameters of 
MaxR (P = 0.020), MaxL (P = 0.012), and AUC (P = 0.006) were sig-
nificantly associated with increased mortality risk.
The association of thrombin generation was further evaluated by 
subgroups defined by traditional risk factors, with data for mortality 
risk by maximum thrombin levels presented in Table 5. There was no 
evidence of a significant interaction of subgroup by higher maximum 
thrombin level for mortality risk.
Cause of death ESPRIT, n (%) SMART, n (%) Total, n (%)
AIDS 7 (11.7) 3 (5.6) 10 (8.8)
Non- AIDS cancer 14 (23.3) 13 (24.1) 27 (23.7)
CVD 8 (13.3) 7 (13) 15 (13.2)
Unwitnessed death 7 (11.7) 5 (9.3) 12 (10.5)
Hepatic 7 (11.7) 3 (5.6) 10 (8.8)
Infection 3 (5) 4 (7.4) 7 (6.1)
CNS disease 3 (5) 0 (0) 3 (2.6)
Renal 0 (0) 2 (3.7) 2 (1.8)
Digestive system disease 1 (1.7) 1 (1.9) 2 (1.8)
Respiratory disease 0 (0) 1 (1.9) 1 (0.9)
Substance abuse 3 (5) 6 (11.1) 9 (7.9)
Unknown 7 (11.7) 9 (16.7) 16 (14)
Total 60 (100) 54 (100) 114 (100)
CNS, central nervous system; CVD, cardiovascular disease.
TABLE  2 Distribution of underlying 
cause of death by study
TABLE  3 Factor levels and odds ratios for mortality. Median (IQR) factor levels for cases and controls and odds ratios for mortality 





(IQR) OR (95% CI)a P- value Adjust. OR (95% CI)b P- value
II (%) 101 (84- 117) 105 (91- 121) 0.56 (0.32- 1) 0.049 0.63 (0.35- 1.13) 0.12
V (%) 111 (87- 135) 98 (85- 120) 1.72 (1.1- 2.69) 0.018 1.73 (1.1- 2.71) 0.017
VII (%) 94 (77- 112) 103 (84- 124) 0.65 (0.41- 1.02) 0.062 0.67 (0.41- 1.09) 0.10
VIII (%) 147 (110- 189) 130 (100- 163) 1.91 (1.25- 2.92) 0.003 1.80 (1.16- 2.8) 0.009
IX (%) 96 (82- 113) 97 (86- 113) 0.83 (0.56- 1.23) 0.36 0.84 (0.56- 1.26) 0.40
X (%) 90 (78- 105) 93 (81- 108) 0.76 (0.42- 1.39) 0.38 0.74 (0.4- 1.38) 0.35
PC (%) 109 (91- 126) 117 (100- 135) 0.44 (0.27- 0.74) 0.002 0.45 (0.26- .77) 0.003
TFPI (ng/mL) 27 (21- 35) 27 (22- 32) 1.39 (0.91- 2.12) 0.13 1.40 (0.9- 2.17) 0.14
AT (%) 127 (110- 140) 130 (114- 143) 0.47 (0.23- 0.95) 0.034 0.51 (0.25- 1.05) 0.068
AT, antithrombin; IQR, interquartile range; PC, protein C; TFPI, tissue factor pathway inhibitor.
aOdds ratio for mortality per 1 log2 higher factor level from unadjusted conditional logistic regression model. 
bOR for mortality per 1 log2 higher factor level, adjusted for age, sex, and race. 
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3.4 | Factor contribution to thrombin generation
In order to determine which factors were responsible for the altered 
thrombin generation between cases and controls, each of the cases 
had their thrombin generation curves re- simulated with each factor 
level set to the median value of the corresponding factor concentra-
tion observed in the HIV control cohort. The protein with the largest 
impact using this methodology was AT. Figure 2A shows the disap-
pearance of differences in simulated thrombin generation between 
the groups when the cases had their AT set to the median value 
for controls of 130% (with all other factor levels for cases left un-
changed). Figure 2B shows a similar diminishing of thrombin genera-
tion differences was seen when a combination of both FV and FVIII 
in cases were altered to the median values in the controls (111% and 
147%, respectively).
This modeling approach was recapitulated with conditional lo-
gistic regression. The association between mortality and MaxL of 
thrombin generation was adjusted for each of the individual factors 
separately, and the OR for mortality associated with a doubling of 
MaxL was determined (Table 6). Individual adjustment for FV, FVIII, 
AT, or PC demonstrated the largest attenuation in the association 
between mortality and MaxL. In addition, adjustment of FV and 
FVIII together had the most substantial impact on attenuating the 
association with mortality.
4  | DISCUSSION
We present data demonstrating for the first time that risk for all- 
cause mortality among HIV+ patients receiving continuous ART is 
associated with a factor compositional imbalance that corresponds 
to an increase in simulated thrombin generation. Mortality was asso-
ciated with increased inflammation, d- dimer, and an altered pro- and 
anticoagulant balance with higher levels of FV and FVIII and lower 
levels of PC and AT, yielding a higher procoagulant state among 
cases of non- violent mortality when compared with controls. These 
findings expand our understanding of HIV- associated abnormalities 
in coagulation biology and the consequences for mortality from a 
broad spectrum of disease, both CVD and non- CVD related.
We have shown in previous analyses of different pathologic 
states that normal range variation in coagulation factor composi-
tion can modulate the relative severity of the thrombin generation 
defect.30,47 The balance between these procoagulant and antico-
agulant processes provides a defense against excessive fluid loss 
(hemorrhage) and against inappropriate vascular occlusion (throm-
bosis). Previous studies have shown that in HIV+ patients, there ex-
ists lower PC and protein S and elevated d- dimer and von Willebrand 
factor compared to HIV- controls.48 Higher fibrinogen has also been 
identified in HIV+ patients.49 We have also shown from the SMART 
study that increased HIV replication after stopping ART correlated 
with increased levels of FVIII and decreased levels of AT and PC, 
resulting in increased thrombin generation in this computational 
model.41 In this current study, both groups of ART- treated HIV+ 
patients had higher average AT than the mean physiologic popula-
tion. This finding is in agreement with Hsue et al,50 who also found 
higher AT levels in HIV patients (both untreated and those receiving 
ART) compared to uninfected controls. That study found the higher 
AT levels contributing to a relatively decreased thrombotic state. In 
contrast, our HIV+ cohort had a significantly higher prothrombotic 
F IGURE  1 Computational model of all patients by survival 
status. Cases (in red) and controls (in blue) are displayed as the 
mean thrombin concentration at each second. The shaded areas 
represent the SEM at those points. Also shown (as a dashed gray 
line) is the curve generated when all coagulation factors are set to 





















(IQR) n = 114
Controls median 
(IQR) n = 318 OR (95% CI)a P- value
Maximum rate 
(nmol/L per s)
0.44 (0.28- 0.62) 0.35 (0.2- 0.56) 1.25 (1.04- 1.51) 0.02
Maximum level 
(nmol/L)
68 (45- 97) 54 (33- 87) 1.31 (1.06- 1.63) 0.012
Clot time (s) 348 (284- 420) 359 (298- 425) 1.04 (0.84- 1.27) 0.75
AUC (μmol/L × s) 18 (11.2- 26) 13.5 (8.7- 22.1) 1.35 (1.09- 1.67) 0.006
AUC, area under curve; IQR, interquartile range.
aOdds ratio for mortality per 1 log2 higher parameter level from unadjusted conditional logistic re-
gression model. 
TABLE  4 Thrombin modeling 
parameters and odds ratios for mortality
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potential than the hypothetical control with all factors at mean 
physiologic levels despite the increase in AT. This increased AT as-
sisted in mediating the combined effects of higher prothrombotic 
factors and decreased TFPI, when compared to physiologic means, 
which were found in both groups of this HIV+ population. As seen 
in Figure 2B, an alteration of the concentrations of FV and FVIII in 
the cases to the level seen in the controls diminished the observed 
differences in thrombin generation between the two groups. This 
particular combination is notable because they are the two proco-
factors of the coagulation system, converted by thrombin to the 
active forms FVa and FVIIIa.51–53 These proteins are the respective 
cofactors of the prothrombinase (FVa–FXa) and intrinsic tenase 
(FVIIIa–FIXa) complex, with the intrinsic tenase being the principal 
generator of FXa and subsequent thrombin generation.
Thrombin’s procoagulant activity is neutralized by the plasma 
serine proteinase inhibitor AT and through the PC anticoagulant 
pathway. The PC anticoagulant pathway plays a major role in the 
balance of procoagulation and anticoagulation, by providing a dy-
namic inhibitory system to regulate thrombin production. Activated 
protein C, produced by the thrombin–thrombomodulin complex, 
inactivates the cofactors FVa and FVIIIa,54 thereby downregulating 
further generation of thrombin and stopping clot propagation. In this 
study, it is the suppression of the anticoagulants PC and AT that al-
lows for the continued formation of the procoagulant complexes by 
not inactivating FVa and FVIIIa, which converts FX to FXa and allows 
for the continuation of thrombin generation. The increase in these 
critical enzymes (FXa and thrombin) also further promotes the ob-
served hypercoagulation in part through the activation of protease- 
activated receptors 1 and 2,55–57 which is seen in this population by 
the increased proinflammatory cytokines such as IL- 6. This com-
bined effect may be driving the excess thrombin generation that is 
seen among the mortality cases.
We have previously reported that risk for all- cause mortality, as 
well as a composite of serious non- AIDS defining conditions, is asso-
ciated with increased levels of d- dimer, a known marker for thrombo-
sis, as well as the inflammatory cytokine IL- 6.7 d- dimer has also been 
shown to be a predictor of mortality in cancer,58,59 acute pulmonary 
embolism,60 and (along with CRP) in acute aortic dissection.61 In this 
study, mortality risk was associated with parameters of thrombin 
generation along with differences in the individual factors FV, FVIIII, 
AT, and PC. Our findings build on our previous work41 demonstrating 
that decreased AT and increased FVIII were the primary proteins re-
sponsible for the increased thrombin generation associated with HIV 
viral replication. Here, we show associations between mortality and 
estimated thrombin generation among ART- treated HIV+ patients 
that is, in part, accounted for by this same pattern of lower AT and 
higher FVIII levels. Cumulatively, these data are consistent with our 
overall hypothesis that HIV- related coagulation abnormalities im-
prove but may persist while on ART, have consequences for a broad 
spectrum of end- organ disease risk, and may be mediated, at least 
TABLE  5 Mortality risk by maximum thrombin level (MaxL) for key subgroups
Cases Controls
OR (95% CI) P- valuea P- valuebNumber Med (IQR) Number Med (IQR)
Age
≤50 years 69 72 (49- 98) 217 53 (31- 87) 1.49 (1.14- 1.96) 0.004 0.15
>50 years 45 67 (38- 96) 101 55 (36- 87) 1.08 (0.77- 1.52) 0.65
Sex
Male 92 62 (42- 95) 257 51 (33- 81) 1.32 (1.04- 1.67) 0.022 0.78
Female 22 84 (74- 108) 61 77 (41- 108) 1.43 (0.85- 2.4) 0.18
Race
Black 23 72 (49- 117) 55 75 (54- 113) 1.04 (0.67- 1.62) 0.87 0.25
Other 91 67 (42- 93) 263 50 (30- 83) 1.39 (1.1- 1.76) 0.006
Hepatitis coinfection
Yes 36 80 (57- 116) 50 71 (57- 97) 1.46 (0.87- 2.43) 0.15 0.52
No 78 65 (38- 91) 268 50 (31- 82) 1.21 (0.95- 1.53) 0.12
HIV RNA
≤500 copies/mL 76 67 (43- 88) 242 51 (31- 81) 1.34 (1.04- 1.74) 0.026 0.59
>500 copies/mL 38 84 (48- 115) 76 69 (44- 100) 1.18 (0.81- 1.74) 0.39
IL- 6
<2.11 pg/mL 30 53 (42- 76) 185 52 (34- 81) 1.08 (0.74- 1.59) 0.69 0.33
≥2.11 pg/mL 80 74 (48- 112) 133 59 (33- 89) 1.36 (1.04- 1.78) 0.023
CI, confidence interval; IQR, interquartile range; OR, odds ratio.
aConditional logistic regression OR for mortality per 1 log2 higher level. 
bP- value for interaction. 
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in part, by changes in coagulation factors as a result of hepatocyte 
dysfunction in the context of systemic inflammation.
This study has several limitations: (i) There are too few events to 
examine associations with specific causes of death or any individual 
end- organ disease condition, and we have limited power for assess-
ing subgroup interactions, (ii) We estimate the kinetics of thrombin 
generation through an empirically validated computational model, 
however, the incompleteness of any coagulation model is a poten-
tial confounder.47 Here, in this focused case- control study, we ask 
the question of whether our previously validated model can identify 
HIV+ patients who die vs those who do not, (iii) Specimens used for 
this study were from adjudicated cases, and controls, enrolled in a 
large clinical outcome trial. The stored plasma allocated for this study 
was collected as EDTA specimens, which precluded functional fac-
tor level measurements. As well, specimens associated with clinical 
events are a precious resource in this context, and we did not have 
any additional plasma available to perform in vitro thrombin gener-
ation assays. As computational modeling has made advancements 
into the area of predictive modeling of hemostatic status, ultimately 
having input concentrations of both antigen and functional activity 
would be optimal, and (iv) Any coagulation related genetic mutations 
such as prothrombin G20210A or FV Leiden, were not accounted for, 
which would also influence the individual’s prothrombotic state.
Determining who is at risk for mortality from thrombotic disorders 
is difficult because the pathogenesis is complicated and multifactorial. 
Risk predictions for thrombotic- related outcomes are mostly based 
upon genetic factors (AT,62 PC,63 and protein S64 deficiencies; FV 
Leiden65 and prothrombin G20210A66 mutations), increases in coagu-
lation factors (notably FVIII,67 FIX,68 FXI69) and environmental factors 
(obesity,70 oral contraceptive use,71 hormone replacement therapy,71 
age,72 alcohol use,73 and potentially smoking74). The heterologous 
presence of any of these circumstances in any individual may still be 
asymptomatic and does not ordinarily necessitate clinical interven-
tion. In HIV+ patients, ART reduces but does not appear to fully nor-
malize abnormalities in coagulation activation. In this study, all HIV+ 
patients were on ART therapy, and we show that that residual abnor-
malities in coagulation factor composition (FV, FVIII, PC, AT), in part, 
resulting from ongoing inflammation (eg, reflected in IL- 6 levels), pro-
mote FXa activity which can become an important contributor to the 
excess thrombin generation observed among mortality cases. Having 
predictive models that evaluate each individual’s specific blood co-
agulation profile may better inform mortality risk, and help identify 
potential treatment interventions, among ART- treated HIV+ persons.
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